ProCE Banner Activity

MARIPOSA: Final Overall Survival of First-line Amivantamab + Lazertinib vs Osimertinib for Untreated EGFRm Advanced NSCLC

Conference Coverage
Slideset

Final overall survival results of the phase III MARIPOSA trial demonstrate a significant improvement with first-line amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant advanced non-small-cell lung cancer.

Released: April 10, 2025

Expiration: October 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc